Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
BALA CYNWYD, Pa., Nov. 10, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2022 operating and financial results.
Related news for (LRMR)
- Larimar Therapeutics Reports Second Quarter 2025 Financial Results
- 24/7 Market News Snapshot 14 August, 2025 – Larimar Therapeutics, Inc. Common Stock (NASDAQ:LRMR)
- Breaking News: MoBot’s Latest Update as of 08/05/25 11:00 AM
- Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
- Breaking News: MoBot’s Latest Update as of 04/30/25 03:00 PM